---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000033"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-05-04T23:59:59+00:00"
generated_at: "2026-06-26T00:50:28.549990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene reports Q1 net loss $79.9M, cash $733M; plans pivotal ALLO-501A trial mid-2022

## Summary
- Net loss $79.9M ($0.56/sh); R&D $60.2M, G&A $19.9M; cash $733.1M at March 31, 2022.
- Pivotal Phase 2 ALPHA2 trial of ALLO-501A in R/R large B cell lymphoma to start mid-2022 using CF1 product.
- FDA granted Orphan Drug Designation for ALLO-605 (TurboCAR) for multiple myeloma; Fast Track for ALLO-316 for RCC.
- Full-year 2022 GAAP OpEx guided at $360-390M, including $90-100M stock-based compensation.
- Cell Forge 1 operational; projected annual capacity of ~20,000 AlloCAR T doses at scale.

## SEC filing metadata
- accession: 0001737287-22-000033
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/0001737287-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000033/allo-20220504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000033
- JSON: https://secwatch.observer/filing/0001737287-22-000033.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.